NURIX THERAPEUTICS INC. - COMMON STOCK

Nurix Therapeutics to Participate in Upcoming Investor Conferences

29 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

11 Jul 2024 16:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day

08 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)

16 Jun 2024 05:30:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)

10 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

29 May 2024 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer

28 May 2024 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Board Chair Transition

20 May 2024 16:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)

14 May 2024 10:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference

07 May 2024 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

16 Apr 2024 18:21:52 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering

11 Apr 2024 23:38:26 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Proposed Public Offering

11 Apr 2024 16:00:01 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

10 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

09 Apr 2024 13:15:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6

09 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

03 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences

02 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)

25 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting

20 Mar 2024 09:40:00 By Nasdaq GlobeNewswire